Sagent Pharmaceuticals Announces Launch of Oxacillin for Injection, USP
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Oxacillin for Injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the twelve-months ended May 2012, the U.S. market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.